Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017

A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report published in the Journal of Clinical Investigation, the team based in the Edwin L. Steele Laboratories for Tumor Biology in the MGH Department of Radiation Oncology describes finding in mouse models how anti-angiogenesis treatment induces a microenvironment that suppresses immune systems actions that would otherwise help to eliminate a tumor. They also developed a potential strategy for getting around this resistance mechanism.

"Deciphering and targeting mechanisms involved in to anti-angiogenic therapy is critical to realizing the full potential of this promising cancer therapy," says Dai Fukumura, MD, PhD, deputy director of the Steele Labs, co-senior author of the paper. "Not only is this the first report investigating the role in anti-angiogenic cancer therapy of a subset of innate immune cells - Ly6Clow or non-classical monocytes - it is also the first to find an immunosuppressive function for these cells and to identify that as the key mechanism conferring resistance to anti-angiogenic therapy."

Angiogenesis inhibitors - often given in combination with traditional therapies - can improve treatment for several types of cancer, both by restricting the growth of new blood vessels and by "normalizing" the abnormal vessels in and around a that can interfere with both chemotherapy and radiation therapy. But resistance to anti-angiogenic therapy limits the drugs' survival benefits. Several studies have suggested a role in the development of resistance for the immune system - particularly innate immune cells that suppress immune activity. But how specific subsets of these cells contribute to resistance has not been defined.

A series of experiments in mouse models of colorectal cancer first revealed that treatments blocking the vascular endothelial growth factor (VEGF) pathway - the target of approved anti-angiogenic drugs - induce the accumulation of monocytes and neutrophils. It soon became apparent that the buildup of non-classical monocytes - a subset previously identified as patrolling healthy blood vessels and possibly having an anti-tumor effect in lung cancer - was responsible for development of an immunosuppressive tumor microenvironment in colorectal cancer.

The research team identified the signaling pathway by which VEGF blockade induces expression of a molecule called CX3CL1 on tumor cells, attracting non-classical monocytes that carry the matching receptor. Those cells, in turn, attract neutrophils with another molecule called CXCL5; and both immune cells express factors that inhibit the proliferation of T cells, reducing the overall immune response to the tumor. Examination of biopsy samples taken from human patients before and after anti-angiogenic therapy revealed that expression of these chemokines - molecules that attract immune - increased in response to anti-VEGF treatment.

Since several methods of experimentally blocking the pathway improved the effects of anti-VEGF therapy in the mouse models, the team collaborated with Massachusetts Institute of Technology investigators to develop a potential gene therapy approach. Utilizing nanoparticle-delivered RNA interference against the interaction between CX3CL1 and its receptor, the approach significantly reduced the infiltration of non-classical monocytes into treated tumors and increased the beneficial effects of anti-VEGF therapy in a .

"Targeting resistance mechanisms can improve the efficacy of anti-angiogenic therapy drugs and help fulfill their promise against cancer," says Fukumura, an associate professor of Radiation Oncology at Harvard Medical School (HMS). "Our study's unveiling of a novel resistance mechanism to anti-VEGF and the molecular mechanism underlying that resistance offers a basis for the development of novel and efficient immunotherapeutic strategies to treat solid tumors."

Rakesh K. Jain, PhD, director of the Steele Labs and co-senior author of the Journal of Clinical Investigation report, adds, "Tumors also escape the immune system through immune checkpoint molecules like PD-1 and CTLA-4, which are the targets of recently approved drugs. But that strategy has been effective only in some tumor types and in only a fraction of patients. Therapeutic strategies based on our findings regarding the immunosuppressive action of non-classical monocytes may prove to have synergistic effect with those approved immune checkpoint inhibitors." Jain is the Cook Professor of Radiation Oncology (Tumor Biology) at HMS.

Explore further: Targeting two angiogenesis pathways could improve results of glioblastoma treatment

More information: Keehoon Jung et al, Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI93182

Related Stories

Targeting two angiogenesis pathways could improve results of glioblastoma treatment

April 4, 2016
Two companion papers from Massachusetts General Hospital (MGH) research teams suggest that targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment inevitably ...

Targeting blood vessels to improve cancer immunotherapy

April 12, 2017
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.

Specialized blood vessels enhance tumor-fighting immunotherapy

April 13, 2017
Scientists from VIB and KU Leuven, together with colleagues from the University of California and the Swiss Institute for Experimental Cancer Research have demonstrated that, anti-angiogenic therapy can improve immune boosting ...

Immune system molecule promotes tumor resistance to anti-angiogenic therapy

August 5, 2013
A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

Blood vessels and the immune system talk to each other; implications for cancer treatment

April 3, 2017
Some cancer therapies aim at stopping tumor growth by affecting the blood vessels that nurture the tumor mass, while others act on the immune system attempting to eliminate the tumor. Researchers at Baylor College of Medicine ...

Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment

May 24, 2017
While target therapies directed toward genetic mutations that drive a tumor's growth have significantly improved the outlook for many patients, they have not been as successful in controlling brain metastases in several types ...

Recommended for you

Discovery of potent parasite protein may lead to new therapeutic options for inflammatory bowel conditions

November 24, 2017
A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn's or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant ...

Druglike molecules produced by gut bacteria can affect gut, immune health

November 23, 2017
Stanford researchers found that manipulating the gut microbe Clostridium sporogenes changed levels of molecules in the bloodstreams of mice and, in turn, affected their health.

Study explores whole-body immunity

November 21, 2017
Over the next few months, millions of people will receive vaccinations in the hope of staving off the flu—and the fever, pain, and congestion that come with it.

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

Atopic eczema—one size does not fit all

November 21, 2017
Researchers from the UK and Netherlands have identified five distinct subgroups of eczema, a finding that helps explain how the condition can affect people at different stages of their lives.

Breast milk found to protect against food allergy

November 20, 2017
Eating allergenic foods during pregnancy can protect your child from food allergies, especially if you breastfeed, suggests new research from Boston Children's Hospital. The study, published online today in the Journal of ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.